31 completed, 13 recruiting, 7 active not recruiting, 6 unknown. 29 Phase 2, 15 Phase 3, 9 Not applicable, 5 Phase 1.
Follow Seminoma: new trials by email Literature Review of Seminoma trials Research Report on Seminoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PRISTINE Trial: PRoton Beam Therapy In Seminoma - Toxicity INvestigation and Evaluation of Outcome protontherapy - Seminoma | Not applicable | Not yet recruiting | Istituto Clinico Humanitas | 20 | 2026-05-01 | 2026-05-22 |
| Sentinel Node Identification Using Gamma and Near-Infrared Imaging in TesticulAr MaLignancies Standard treatment: orchiectomy followed by drug therapy and, if necessary, retroperitoneal lymphadenectomy, sentinel lymph node mapping using technetium-99m (Tc-99m) and indocyanine green (ICG) with subsequent orchiectomy - Germ Cell Tumor of Testis | Recruiting | N.N. Petrov National Medical Research Center of Oncology | 60 | 2026-04-01 | 2026-08-27 | |
| Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer primary RPLND for low-stage metasatatic seminoma, 3 courses of chemotherapy; Blemocin, Etoposide and Platinum (BEP) - Testicular Cancer, Seminoma | Not applicable | Recruiting | Sahlgrenska University Hospital | 160 | 2026-03-19 | 2026-03-27 |
| Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors Audiometric Test, Cisplatin, Computed Tomography - Hearing Loss, Metastatic Malignant Germ Cell Tumor | Phase 1 | Recruiting | City of Hope Medical Center | 44 | 2026-02-19 | 2026-04-17 |
| A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases Retroperitoneal Lymph Node Dissection - Testicular Cancer | Phase 2 | Recruiting | Western University, Canada | 30 | 2025-07-17 | 2025-07-20 |
| THERApy De-escalation for TESTicular Cancer retroperitoneal lymph node dissection, Carboplatin AUC10 - Seminoma | Recruiting | Queen Mary University of London | 30 | 2024-06-24 | 2026-03-02 | |
| High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors High-dose chemotherapy (TI- 2 cycles, CE- 3 cycles ) - Germ Cell Tumor | Phase 2 | Recruiting | N.N. Petrov National Medical Research Center of Oncology | 25 | 2024-03-01 | 2025-08-03 |
| Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring Oncological Follow-up - Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor | Phase 2 | Recruiting | Centre Oscar Lambret | 88 | 2024-02-28 | 2026-03-18 |
| Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer Robot-assisted ICG-guided sentinel lymph node biopsy - Germ Cell Tumor, Seminoma | Not applicable | Recruiting | Heinrich-Heine University, Duesseldorf | 44 | 2023-09-06 | 2025-09-15 |
| PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND Robot-assisted retroperitoneal lymph node dissection, Adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin - Seminoma | Phase 2 | Recruiting | Heinrich-Heine University, Duesseldorf | 60 | 2023-08-28 | 2025-09-15 |
| De-escalation Study for Stage IIa/IIb < 3 cm Seminoma Radiotherapy boost, Carboplatin AUC7, 3 cycles of EP - Seminoma, Stage II | Phase 2 | Recruiting | Centre Leon Berard | 90 | 2022-09-06 | 2026-09-15 |
| R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma Robotic Retroperitoneal Lymph Node Dissection (RPLND) - Lymphadenopathy Retroperitoneal, Stage II Testicular Seminoma | Not applicable | Recruiting | University Health Network, Toronto | 25 | 2022-02-23 | 2025-12-19 |
| Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma Radiotherapy - Seminoma | Not applicable | Recruiting | Tata Memorial Centre | 74 | 2021-12-01 | 2025-02-11 |
| A Phase II Trial of Cabozantinib With Patients With Refractory GCTs Cabozantinib - Germ Cell Tumor, Seminoma | Phase 2 | Completed | Jennifer King | 50 | 2021-06-10 | 2026-10-16 |
| A Study of miRNA 371 in Patients With Germ Cell Tumors Biomarker Analysis, Blood Product Collection - Germ Cell Tumor, Metachronous Malignant Neoplasm | Active not recruiting | SWOG Cancer Research Network | 956 | 2020-07-28 | 2026-03-12 | |
| Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma Carboplatin, Cisplatin, Etoposide - Seminoma, Testicular Cancer | Phase 2 | Active not recruiting | Swiss Cancer Institute | 135 | 2019-07-29 | 2026-01-20 |
| Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Durvalumab, Tremelimumab - Germ Cell Tumor, Nonseminomatous Germ Cell Tumor | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2017-05-15 | 2026-09-18 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| MicroRNA as Markers in Testicular Cancer Biomarker analysis - Testicular Germ Cell Cancer, Seminoma | Recruiting | Haukeland University Hospital | 350 | 2016-12-31 | 2022-08-08 | |
| Epigenetic Integrity of Spermatozoa in Patients With Germinal Testicular Tumours Extraction genomic DNA, Analysis of methylation profiles of numerous GSI and TE, Analysis of methylation for the whole genome (sub-population of 15 samples from group 1) - Seminomas | Unknown | Centre Hospitalier Universitaire Dijon | 90 | 2016-09-01 | 2017-08-25 |
Showing 20 of 62. Sign in to see all of them.
Testicular Neoplasms (40) · Endodermal Sinus Tumor (29) · Teratoma (27) · Carcinoma, Embryonal (25) · Testicular Germ Cell Tumor (21) · Teratoma, Testicular (18) · Carcinoma, Ovarian Epithelial (15) · Breast Neoplasms (14) · Burkitt Lymphoma (14) · Hodgkin Disease (14) · Leukemia, Lymphocytic, Chronic, B-Cell (14) · Lymphoma, Follicular (14) · Lymphoma, Large B-Cell, Diffuse (14) · Lymphoma, Large-Cell, Immunoblastic (14)
Neoplasms by Histologic Type (62) · Germinoma (59) · Neoplasms, Germ Cell and Embryonal (55) · Neoplasms (52) · Urogenital Diseases (45) · Endocrine System Diseases (43) · Genital Diseases (43) · Gonadal Disorders (43) · Neoplasms by Site (43) · Urogenital Neoplasms (43) · Endocrine Gland Neoplasms (42) · Male Urogenital Diseases (41) · Genital Diseases, Male (40) · Genital Neoplasms, Male (40) · Testicular Diseases (40)
Cisplatin (12) · Etoposide (11) · Carboplatin (9) · Filgrastim (7) · Ifosfamide (7) · Paclitaxel (7) · Bleomycin (6) · Radiotherapy (5) · Magnetic Resonance Spectroscopy (4) · Peripheral Blood Stem Cell Transplantation (3) · pegfilgrastim (3) · CTLA-4 Antigen (2) · Cyclophosphamide (2) · Granulocyte Colony-Stimulating Factor (2) · Imatinib Mesylate (2)
Fred Hutchinson Cancer Center (7) · Memorial Sloan Kettering Cancer Center (6) · European Organisation for Research and Treatment of Cancer - EORTC (4) · National Cancer Institute (NCI) (4) · Alliance for Clinical Trials in Oncology (2) · City of Hope Medical Center (2) · Heinrich-Heine University, Duesseldorf (2) · Medical Research Council (2) · N.N. Petrov National Medical Research Center of Oncology (2) · Swiss Cancer Institute (2) · AHS Cancer Control Alberta (1) · Barts & The London NHS Trust (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Cancer Treatment Centers of America (1) · Centre Hospitalier Universitaire Dijon (1)
United States (30) · United Kingdom (12) · France (9) · Germany (9) · Canada (7) · Netherlands (6) · Norway (6) · Belgium (5) · Italy (5) · Spain (5) · Switzerland (5) · Denmark (4) · Austria (3) · Israel (3) · Slovakia (3)
Robert J. Motzer, MD (4) · Alexandros Papachristofilou, MD (2) · Darren Feldman, MD (2) · Aleksei M Belyaev, MD,DSc,Prof. (1) · Alex Chehrazi-Raffle (1) · Anastasios Raptis, MD (1) · Christopher Ryan (1) · Claude Sportes, MD (1) · Craig R Nichols (1) · David Hockenbery, MD (1) · David P. Dearnaley, MD, FRCP, FRCR (1) · Dean F. Bajorin, MD (1)
PMID 15459300, PMID 16039331, PMID 16849762, PMID 17235042, PMID 17634488, PMID 18974373, PMID 19451433, PMID 19547919, PMID 21059637, PMID 21282539, PMID 30563754, PMID 31136925, PMID 31969335, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34716198, PMID 35298280, PMID 35599187, PMID 36228644, PMID 36913642, PMID 38243705, PMID 38358334, PMID 39028926, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40203124, PMID 40402690, PMID 40588371, PMID 41672597, PMID 41823372, PMID 41892875, PMID 41995270, PMID 42499790
P30CA033572 (2), U10CA031946 (2), 2009 (1), 2014 (1), 2019 (1), P30CA008748 (1), P30CA014089 (1), R01CA093891 (1), U10CA180821 (1), U10CA180888 (1), UG1CA189974 (1)